Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity
Open Access
- 20 July 2021
- journal article
- research article
- Published by Springer Nature in IIC - International Review of Intellectual Property and Competition Law
- Vol. 52 (7) , 825-851
Abstract
EU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioning their drugs before and after the +1 came into effect. The results show that: (i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and (ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.Keywords
Funding Information
- University of Cambridge
This publication has 22 references indexed in Scilit:
- Use of medicines for carved out indications - Time for a change in approach?Journal of Commercial Biotechnology, 2013
- Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical PatentsPLOS ONE, 2012
- Drug Repurposing: Far Beyond New Targets for Old DrugsThe AAPS Journal, 2012
- Regulatory Considerations and Strategies for Drug Repositioning2012
- Clinical and Operational Considerations in Repositioning Marketed Drugs and Drug Candidates2012
- Business Development Strategies in the Repositioning Industry2012
- Drug Repositioning Efforts by Nonprofit Foundations2012
- Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch LegislationInternational Journal of the Economics of Business, 2011
- Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer ChemopreventionCancer Prevention Research, 2008
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004